- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02872844
Local Heat-Stress as a Mechanism of Hearing Preservation
Local Heat-Stress as a Mechanism of Hearing Preservation in Adults Treated With Cisplatin: A Pilot Study
Study Overview
Detailed Description
Evidence from the laboratory over the past 10-15 years has demonstrated that heat stress to the ear is otoprotectant against a variety of insults. The strongest evidence supports heat-shock protein 70 (Hsp70) as a key facilitator in this protection. Hsp70 is well established as a cell stabilizer, especially for cells undergoing significant stress. Hsp70 has been shown to protect against cisplatin-induced ototoxicity. Induction of Hsp70 may be accomplished pharmacologically, by whole-body heat stress, or by local heat stress. A form of local heat-stress is already employed in the common clinical setting of the warm caloric. This vestibular test has been in place since the early 20th century with a variety of studies evaluating the patient vestibular response to a variety of times and temperatures. Current clinical practice recommends either water or air calorics of 45°C or 50°C (respectively) at 45-60 seconds.
Several studies have described administering prolonged caloric stimulation to individual subjects without ill effect. Patients are able to tolerate stimulation up to 60 minutes without intolerable nystagmus or vertiginous symptoms or significant injury. Thus, it is feasible to provide warm stimulus to the ear for the recommended time of 30 minutes at the recommended temperature of 50°C (air) without significant risk to the patient.
The purpose of this study is to evaluate the impact of heat stress to the inner ear as an otoprotectant intervention against cisplatin-induced hearing loss. Patients that meet inclusion criteria will be offered audiometric evaluation before each cisplatin treatment and at 1, 3, 6, and 12 months following their chemotherapy. Patients will undergo their heat-stress 5-7 hours prior to their cisplatin treatment. Patients will serve as their own controls with one ear randomly receiving treatment and the other not. The primary outcome will be audiometric testing. Blood samples will be collected for serum levels of Hsp70 as a secondary outcome. A sample size of 12 achieves 80% power to detect a 0.9 standard deviation difference between ears using a two-sided paired t-test at 0.05 significance level.
Study Type
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Nebraska
-
Omaha, Nebraska, United States, 68198
- University of Nebraska Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Any patient undergoing total cisplatin in total doses > 100mg/m2.
- Written consent.
- Age > 19 years.
Exclusion Criteria:
- Inability to tolerate the intervention
- Exposure to cisplatin treatment without intervention.
- Head and neck carcinoma
- Baseline asymmetric hearing loss.
- Pregnant or breastfeeding women.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Heat-stress
Each participant will undergo a 30-minute heat stress to one randomized ear.
The participant will be reclined and the hot air caloric at 50°C applied by a licensed, unblinded audiologist for 30 minutes.
|
Each patient will undergo a 30-minute heat stress to one ear.
For randomization, the left ear will be treated in patients with a registration number ending with an odd number and the right for even numbers.
An ICS AirCal3 Research Strategy (Otometrics) system attached to an Intel Core 15vPro Thinkpad (IBM) laptop is used within the audiometry department of a separate outpatient clinic.
The patients will be reclined and the hot air caloric at 50°C applied by a licensed, unblinded audiologist for 30 minutes.
The patients will be allowed to fixate and use whatever means they prefer for entertainment during the intervention.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Audiometric Effect
Time Frame: One year
|
Audiometric evaluation will serve as the primary measure of outcome.
|
One year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Paul Judge, MD, University of Nebraska
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0170-16-FB
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hearing Loss
-
MED-EL Elektromedizinische Geräte GesmbHCompletedHearing Loss | Hearing Loss, Sensorineural | Hearing Loss, Bilateral | Hearing Loss, Conductive | Hearing Loss, Unilateral | Hearing Loss, MixedAustria, Germany, United Kingdom
-
Oticon MedicalCompletedEar Diseases | Hearing Loss, Conductive | Hearing Loss Mixed | Hearing Disability | Conductive Hearing Loss | Conductive Hearing Loss, Bilateral | Conductive Hearing Loss, UnilateralUnited Kingdom
-
Oticon MedicalNot yet recruitingSensorineural Hearing Loss, Bilateral | Sensorineural Hearing Loss, Severe | Sensorineural Hearing Loss, Profound
-
University of California, San FranciscoPatient-Centered Outcomes Research InstituteRecruitingHearing Loss | Hearing Loss, Sensorineural | Hearing Loss, Bilateral | Hearing Loss, Conductive | Hearing Loss, Noise-Induced | Hearing Loss, Unilateral | Hearing Loss, Mixed | Hearing Disorders in ChildrenUnited States
-
Manchester University NHS Foundation TrustUniversity of ManchesterCompletedCochlear Hearing Loss | Sensorineural Hearing Loss, BilateralUnited Kingdom
-
Truway Health, Inc.Enrolling by invitationSensorineural Hearing Loss | Tinnitus | Sudden Hearing Loss | Acoustic Trauma | Inner Ear Injury | Noise-Induced Hearing Loss | Vestibular DysfunctionUnited States
-
Wonju Severance Christian HospitalRecruitingHearing Loss, Sudden | Sudden Hearing Loss | Hearing Loss, Idiopathic Sudden Sensorineural | SSNHL(Sudden Sensory Neural Hearing Loss)Korea, Republic of
-
Envoy Medical CorporationActive, not recruitingSensorineural Hearing Loss | Sensorineural Hearing Loss (Disorder) | Sensorineural Hearing Loss, Bilateral | Sensorineural Hearing Loss, Severe | Sensorineural Hearing Loss, Profound | Sensori-Neural DeafnessUnited States
-
Oticon MedicalCompletedConductive Hearing Loss | Conductive and Sensori-neural Hearing Loss in the Same Ear | Unilateral, Profound Sensori-neural Hearing LossUnited States
-
Frequency TherapeuticsCompletedHearing Loss, Sensorineural | Presbycusis | Noise Induced Hearing Loss | Sudden Hearing LossUnited States
Clinical Trials on ICS AirCal3
-
Zagazig UniversityActive, not recruiting
-
Brigham and Women's HospitalPatient-Centered Outcomes Research InstituteNot yet recruitingAsthma | Asthma Chronic | Asthma Severe Persistent With Exacerbation | Asthma Moderate Persistent With ExacerbationUnited States
-
Rabin Medical CenterUnknown
-
NorthShore University HealthSystemCompleted
-
Second Affiliated Hospital, School of Medicine,...Not yet recruiting
-
NHS TaysideNHS FifeWithdrawnChronic Obstructive Pulmonary DiseaseUnited Kingdom
-
Assiut UniversityNot yet recruiting
-
Region SkaneLund UniversityRecruiting
-
Hoffmann-La RocheCompletedAsthmaUnited States, Canada, United Kingdom, Sweden, France, Ireland
-
KU LeuvenUnknownChronic Obstructive Pulmonary Disease | Asthma | Overlap SyndromeBelgium